Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
  • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/28—Phosphorus compounds with one or more P—C bonds
  • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
  • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
  • C07F9/3834—Aromatic acids (P-C aromatic linkage)

Definitions

• the invention relates to compositions and methods for the treatment of proliferative disorders, including but not limited to cancer.
• New cell antiproliferative agents, and anticancer therapeutics in particular, are needed which are useful in inhibiting proliferation of and/or killing cancer cells.
• such agents are needed which are selective in the killing of proliferating cells such as tumor cells, but not normal cells.
• Antineoplasitc agents are needed which are effective against a broad range of tumor types.
• the biologically active compounds are in the form of certain substituted (Z)-styrylbenzyl sulfones, and pharmaceutically acceptable salts thereof. It is an object of the invention to provide compounds, compositions and methods for the treatment of cancer and other cell proliferative diseases.
• the invention is directed to novel compounds of formula I:
• Ri and R 2 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxy, carboxy(C1-
• R 3 and R are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxy, carboxy(C1-C3)alkoxy, hydroxy, (C2-C6)hydroxyalkyl, phosphonato, amino, (C1-C6)acylamino, sulfamyl, acetoxy, di(C1-C6)alkylamino(C2-
• the benzyl nucleus i.e., the ring system containing R 3 and R 4
• the benzyl nucleus is at least monosubstituted, that is, at least one of R 3 and R 4 is other than hydrogen.
• Ri and R 2 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy and acetoxy, while R 3 and R 4 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro and amino.
• the substituents in one embodiment are located at the 4- and/or 2-positions, that is, the compounds have the formula II:
• Ri, R 2 , R 3 and R 4 are defined as above, wherein at least one or both of R 3 and R 4 are other than hydrogen.
• R 4 is other than hydrogen, particularly halogen.
• both R 3 and R are other than hydrogen.
• one or both of R 3 and R 4 are halogen, or all of Ri, R 2 , R 3 and R are halogen.
• (Z)-styryl benzylsulfides are provided which, are useful as intermediates in the preparation of (Z)-styryl benzylsulfones.
• the (Z)-styryl benzylsulfides have the formula:
• compositions comprising a pharmaceutically acceptable carrier and at least one compound according to formula I, or pharmaceutically acceptable salt thereof.
• a method of treating an individual for a cell proliferative disorder comprises administering to said individual an effective amount of at least one compound according to formula I, or pharmaceutically acceptable salt thereof.
• a method of inducing apoptosis of tumor cells in an individual afflicted with cancer comprising administering to said individual an effective amount of at least one compound according to formula I, or pharmaceutically acceptable salt thereof.
• alkyl by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon radical, including di- and multi-radicals, having the number of carbon atoms designated (i.e. C1-C6 means one to six carbons) and includes straight or branched chain groups. Most preferred is C1-C3 alkyl, particularly ethyl and methyl.
• alkoxy employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers. Preferred are C1-C3 alkoxy, particularly ethoxy and methoxy.
• (C2-C6)acylamino means a radical containing a two to six carbon straight or branched chain acyl group attached to a nitrogen atom via the acyl carbonyl carbon. Examples include -NHC(O)CH 2 CH 2 CH 3 and - NHC(O)CH 2 CH2CH2CH 2 CH3.
• carboxy(C1-C3)alkoxy means a radical in which the carboxy group -COOH is attached to a carbon of a straight or branched chain alkoxy group containing one to three carbon atoms.
• the radical thus contains up to four carbon atoms. Examples include HOC(O)CH 2 CH 2 CH O- and HOC(O)CH 2 CH 2 O-.
• di(C1-C6)alkylamino(C2-C6)alkoxy means (alkyl) 2 N(CH 2 ) n O- wherein the two alkyl chains connected to the nitrogen atom independently contain from one to six carbon atoms, preferably from one to three carbon atoms, and n is an integer from 2 to 6.
• n is 2 or 3.
• the alkyl groups are methyl, that is, the group is the dimethylaminoethoxy group, (CH3) 2 NCH 2 CH 2 O-.
• halo or halogen by themselves or as part of another substituent mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
• hydroxyalkyl means an alkyl radical wherein one or more of the carbon atoms is substituted with hydroxy. Examples include -CH 2 CH(OH)CH 3 and -CH 2 CH 2 OH.
• phosphonato means the group -PO(OH) 2 .
• sulfamyl means the group -SO2NH 2 .
• substituted means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
• subject is meant an animal or a human being. Detailed Description of the Invention
• certain (Z)-styrylbenzyl sulfones and pharmaceutically acceptable salts thereof are provided for inhibiting proliferation of cancer cells. They are believed to be effective in killing tumor cell types without killing normal cells.
• the compounds of the invention are believed to induce apoptosis of tumor cells and cell death.
• the compounds are believed effective against a broad range of tumor types, including but not limited to the following: breast, prostate, ovarian, lung, colorectal, brain (i.e, glioma) and renal.
• the compounds are also believed effective against leukemic cells.
• the compounds of the invention are also believed useful in the treatment of non-cancer cell proliferative disorders, including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• non-cancer cell proliferative disorders including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• the substituted (Z)-styrylbenzylsulfones of the invention are prepared by the nucleophilic addition of the appropriate thiol to substituted phenylacetylene with subsequent oxidation of the resulting sulfide by hydrogen peroxide to yield the Z-styrylbenzylsulfone.
• a substituted or unsubstitued sodium benzylthiolate prepared from an appropriate substituted or unsubstitued sodium benzyl mercaptan, is allowed to react with the appropriate substituted phenylacetylene forming the pure Z-isomer of the corresponding substituted (Z)-styrylbenzylsulfide in good yield.
• the substituted (Z)-styrylbenzylsulf ⁇ de intermediate is oxidized to the corresponding sulfone in the pure Z- isomeric form by treatment with an oxidizing agent, such as hydrogen peroxide.
• the compounds of the present invention may take the form or pharmaceutically acceptable salts.
• pharmaceutically acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable.
• Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid.
• organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicyclic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2- hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, algenic, beta-hydroxybutyric, salicyclic, galact
• Suitable pharmaceutically acceptable base addition salts of compounds of formula I include metallic salts made from calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'- dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of formula I by reacting, for example, the appropriate acid or base with the compound of formula I.
• the compounds of the invention may be administered to individuals (mammals, including animals and humans) afflicted with cancer.
• non-cancer cell proliferative disorders that is, cell proliferative disorders which are characterized by benign indications.
• disorders may also be known as "cytoproliferative” or “hyperproliferative” in that cells are made by the body at an atypically elevated rate.
• disorders include, but are not limited to, the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
• the specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration.
• a daily dosage of from about 0.05 to about 50 mg/kg/day may be utilized. Higher or lower doses are also contemplated.
• the compounds of the invention may be administered for therapeutic effect by any route, including oral and parenteral administration.
• Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravaginal, intravesical (e.g., into the bladder), intradermal, topical or subcutaneous administration.
• Also contemplated within the scope of the invention is the instillation of drug in the body of the patient in a controlled formulation, with systemic or local release of the drug to occur at a later time.
• the drug may localized in a depot for controlled release to the circulation, or for release to a local site of tumor growth.
• the compounds of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier.
• the active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent.
• pharmaceutically acceptable carrier is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and to deleterious to the
• the active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice.
• the active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Alphonso Gennaro, ed., Remington's Pharmaceutical Sciences, 18th Ed., (1990) Mack Publishing Co., Easton, PA.
• Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions.
• the active agent may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol.
• a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol.
• Solutions for parenteral administration preferably contain a water soluble salt of the active agent.
• Stabilizing agents, antioxidizing agents and preservatives may also be added. Suitable antioxidizing agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA.
• Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol.
• the composition for parenteral administration may take the form of an aqueous or nonaqueous solution, dispersion, suspension or emulsion.
• the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms.
• the active agent may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents.
• the active agent may be combined with carboxymethylcellulose calcium, magnesium stearate, mannitol and starch, and then formed into tablets by conventional tableting methods.
• Example 1 (Z)-2,4-difluorostyryl-4-chlorobenzylsulfone
• a solution of 2,4-difluorophenylacetylene (0.02 mol), 4- chlorobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-2,4-difluorostyryl-4- chlorobenzylsulfide.
• the title compound is obtained following oxidation of the sulfide, according to the General Procedure.
• Example 4 (Z)-2,4-dimethylstyryl-4-chlorobenzylsulfone
• a solution of 2,4-dimethylphenylacetylene (0.02 mol), 4- chlorobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-2,4-dimethylstyryl-4- chlorobenzylsulfide.
• the title compound is obtained following oxidation of the sulfide, according to the General Procedure.
• Example 8 (Z)-2,3-dichlorostyryl-2-chloro-4-fluorobenzylsulfone
• a solution of 2,3-dichlorophenylacetylene (0.02 mol), 2-chloro-4- fluorobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-2,3-dichiorostyryl-2- chloro-4-fluorobenzylsulfide.
• the title compound is obtained following oxidation of the sulfide, according to the General Procedure.
• Example 12 (Z)-2,4-dimethoxystyryl-2,4-dimethoxybenzylsulfone
• a solution of 2,4-dimethoxyphenylacetylene (0.02 moi), 2,4- dimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-2,4- dimethoxystyryl-2,4-dimethoxybenzylsulfide.
• the title compound is obtained following oxidation of the sulfide, according to the General Procedure.
• Example 19 (Z)-2,4-difluorostyryl-2-aminobenzylsulfone
• a solution of 2,4-difluorophenylacetylene (0.02 mol), 2- aminobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-2,4-difluorostyryl-2- aminobenzylsulfide.
• the title compound is obtained following oxidation of the sulfide, according to the General Procedure.
• the total number of viable cells is determined 96 hours later by trypsinizing the wells and counting the number of viable cells, as determined by trypan blue exclusion, using a hemacytometer. Normal HFL are treated with the same compounds under the same conditions of concentration and time.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=23036961

Family Applications (1)

Country Status (5)

Cited By (3)

Families Citing this family (7)

Citations (2)

Family Cites Families (16)

• 2002
  • 2002-02-26 JP JP2002567281A patent/JP2004521126A/ja active Pending
  • 2002-02-26 US US10/469,056 patent/US6833480B2/en not_active Expired - Lifetime
  • 2002-02-26 CA CA002439256A patent/CA2439256A1/en not_active Abandoned
  • 2002-02-26 WO PCT/US2002/005817 patent/WO2002067913A1/en not_active Ceased
  • 2002-02-26 EP EP02714999A patent/EP1379228A4/en not_active Withdrawn

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events